Companies › Guangzhou FineImmune Biotechnology
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FIT003 TAL-T (Tumor Associated Lymph node T cell) Autologous tumor-associated lymph node T cells, expanded ex vivo | – | Phase 1 | Advanced Solid Tumor; Tumor Associated Lymph Node T Cell | Dec 2026 |
| Super1 TCR-T T-cell receptor engineered T cell targeting NY-ESO-1 | NY-ESO-1 | Phase 1 | Sarcoma | Apr 2027 |
| Super CAR-T GPC3-targeted CAR-T cell therapy | GPRC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06302062 | FIT003 TAL-T (Tumor Associated Lymph node T cell) | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2025 |
| NCT06716619 | FIT003 TAL-T (Tumor Associated Lymph node T cell) | Phase 1 | Tumor Associated Lymph Node T Cell | Oncology | Dec 2026 |
| NCT06942143 | Super1 TCR-T | Phase 1 | Sarcoma | Oncology | Apr 2027 |
| NCT07493044 | Super CAR-T | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Oncology | Apr 2028 |
AstraZeneca OriCell Therapeutics Takara Bio TCRCure Biopharma
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.